Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial

There is no available effective systemic treatment for patients with advanced hepatocellular carcinoma (HCC) who are intolerant of sorafenib or who have disease that has progressed on sorafenib. In Phase I and II studies, tivantinib (ARQ 197), an oral inhibitor of MET, demonstrated promising antitum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepat Oncol
Main Authors: Rimassa, Lorenza, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Finn, Richard S, Raoul, Jean-Luc, Schwartz, Lawrence H, He, Aiwu Ruth, Trojan, Joerg, Peck-Radosavljevic, Markus, Abbadessa, Giovanni, Goldberg, Terri, Santoro, Armando, Bruix, Jordi
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2014
Assuntos:
Clinical Trial Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095177/
https://ncbi.nlm.nih.gov/pubmed/30190953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.14.3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados